Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Prospidium”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 91 records · Page 5Linked to original sources
PubMed1985

[Correction of immunoregulatory disorders in seronegative and seropositive rheumatoid arthritis].

A study was made of the effect of the drugs with an immunostimulant (T-activin, levamisole) and immunosuppressant (prospidin) activity on the synthesis of IgA, IgM and IgG in vitro in lymphoid cultures of 7 healthy donors, 16 patients with seropositive and 9 patients with seronegative rheumatoid arthritis (RA). It was shown that the model of the synthesis of immunoglobulins in vitro demonstrates the impairment of T-B-cell cooperation of lymphocytes in RA patients. It was establised that the effect of immunologically active drugs on the synthesis of immunoglobulins depends on the character of the drug immunotropic action and initial functional activity of the immunoregulatory T-lymphocytes. Like polyclonal mitogens, levamisole and, to a greater extent, T-activin stimulating the initially low activity of T helpers increase spontaneous synthesis of immunoglobulins in lymphoid cultures of patients with seronegative RA, whereas in seropositive RA, these drugs stimulating the initially low activity of T suppressors carrying Fc gamma-receptors inhibit this process. Prospidin inhibit the synthesis of immunoglobulins equally in both RA patterns. Indications and contraindications for administration of he immunologically active drugs on a clinical bases are discussed.

Adjuvants, Immunologic↗
PubMed1985

[Radiotherapy and combined chemo- and radiotherapy of patients with squamous cell lung cancer (randomized study)].

A randomized study on the results of treatment of 76 cases of squamous cell carcinoma of the lung was conducted at the Center in 1976-1981. Radiation and chemoradiation procedures were studied in two groups of patients. The immediate results of chemoradiation therapy were somewhat better as compared with radiation treatment alone. However, no significant increase in survival rates was recorded. The toxicity of the chemotherapeutic procedures used was shown. Total focal dose was increased to 90-120 Gy and longer survival was registered as a result of consistent application of uneven irradiation and open fields in gamma therapy.

Adult↗
PubMed1985

Prospidin combined to preoperative irradiation in head and neck cancer.

Twenty-seven patients with operable squamous cell cancer of head and neck were randomized into the study. Twelve patients received Prospidin combined to preoperative radiotherapy and fourteen patients were treated with preoperative radiotherapy alone. The daily dose of the drug was from 0.70 mg/kg to 2 mg/kg and the total dose during preoperative radiotherapy was between 1800 mg and 2250 mg with a mean of 2073 mg. The recurrence rate was in patients receiving Prospidin three out of twelve and in patients treated with irradiation alone four out of fourteen during the observation time of 33 months. In the present study Prospidin combined with preoperative radiotherapy had no advantage as compared to irradiation alone.

Cobalt Radioisotopes↗
PubMed1983

[Clinico-pharmacological study of prospidin].

Different schemes of prospidin administration to 54 patients were evaluated. Stage IV paresthesia or renal derangements are limitations of prospidin treatment due to its toxicity. Rheovasographic studies established that disorders in vascular tension are responsible for paresthesia development. The best results were obtained with the administration of 300-400 mg every other day for 2-3 weeks. Schemes of combined administration of prospidin and cyclophosphamide and bleomycin were worked out (58 cases). Therapeutic effect was recorded in the treatment of melanoma, carcinoma of the lip, tongue, nasopharynx, salivary gland and skin. Prospidin, cyclophosphamide and radiation therapy were successfully used in the management of small cell carcinoma of the lung.

Adult↗
PubMedDate not supplied

[Effect of spirobramin and prospidin on immunogenesis].

The immunosuppressant effects of the antineoplastic piperazine drugs spirobramine and prospidin in respective doses of 500 and 600 mg/kg (1/2 of the LD50) were studied in experiments on cats. Spirobramine was shown to exert a more pronounced immunoinhibitory action on the primary and secondary immune response induced by sheep red blood cells.

Animals↗
PubMed1983

[Use of prospidin in the combination chemotherapy of recurrences of generalized forms of lymphogranulomatosis].

Combined chemotherapy (prospidin, cyclophosphamide, vincristine and prednisolone) (PCVP) was given to 32 patients with recurrent generalized forms of Hodgkin's disease. Remission was reliably established in 75% of patients; its mean duration was 2.8 months. 15 patients received repeated courses of complex chemotherapy, including prospidin; it proved effective in 12 of them. Mean duration of remission was 2.7 months. Toxic side--effects were insignificant and subsided quickly. The results of the study point to the effectiveness of PCVP scheme application in patients with recurrent generalized forms of Hodgkin's disease.

Adult↗
PubMed1983

An anticancer drug prospidine: failure to reveal antimitotic and clastogenic action on regenerating mouse liver.

Prospidine is an anticancer drug used in oncological practice in the USSR. It is characterized by only a slight toxicity and the absence of such side-effect as the hemopoiesis suppression. The mechanism of tumor growth inhibition by prospidine is still open to question. The present study was undertaken to reveal the potential mutagenic properties of prospidine, using regenerating mouse liver as rapidly proliferating cell system. Animals were given a single (900 or 1500 mg/kg) or daily (200 mg/kg for 9 days) injections of prospidine before or after partial hepatectomy. The mitotic activity, the duration of the cell cycle periods and the frequency of chromosome aberrations in ana-telophase were determined. The data show that unlike other alkylating drugs prospidine fails to suppress cell proliferation or to induce marked chromosome-breaking effects. The only mild effect observed was some prophase and prometaphase prolongation.

Animals↗
PubMed1980

Effects of prospidine on survival and growth of mammalian cells in culture.

The effects of prospidine, chemically known as 3, 12-diaza-6,9 diazoniadispiro[5.2.5.2]hexadecane,3,12-bis(3-chloro-2-hydroxypropyl)-dichloride (NSC-166100), on cell viability, growth, and colony formation were investigated in several mammalian cell lines. Cell cycle progression and the terminal point of action of the drug were monitored by flow cytometry. Prospidine was cytostatic for two suspension cultures (Friend leukemia and L1210 cells) at a concentration of 10 mg/ml during the first cell cycle after exposure to the drug. Cells were blocked in G2 at lower concentrations of prospidine (e.g., 1.0 mg/ml) but only after 12--24 hours of continuous exposure, i.e., during the second cell cycle in the presence of drug. Cells could be observed to accumulate in G2 by 24 hours even if prospidine (0.1 mg/ml) was removed after 12 hours. A short incubation with a liver cytosol fraction (30 min) or with cultured cells (12 hr) failed to enhance the potency of the drug. Formation of colonies of the adherent Chinese hamster ovary cell line was inhibited by 50% following 24-hour exposure to 1.1 mg prospidine/ml. Under culture conditions in which cells were blocked in G2, their RNA content increased only slightly, but the incorporation of [5-(3)H]uridine into RNA was suppressed by 15--20%. Incubation of cells with prospidine increased the stability of DNA in situ to acid-induced denaturation, which thus suggested that the drug may interact with cellular DNA.

Animals↗